Celldex Therapeutics reported $14.84M in Selling and Administration Expenses for its fiscal quarter ending in September of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.84B 205M Sep/2026
Agenus USD 6.21M 4.34M Mar/2026
Amgen USD 1.68B 40M Sep/2026
Bristol-Myers Squibb USD 1.7B 127M Sep/2026
Celldex Therapeutics USD 14.84M 1.74M Sep/2026
Glaxosmithkline GBP 2.38B 264M Sep/2026
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Northwest Biotherapeutics USD 6.54M 534K Mar/2026
Pfizer USD 3.28B 132M Sep/2026
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
Roche Holding CHF 6.37B 908M Jun/2026